Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (9): 1059-1065.doi: 10.12092/j.issn.1009-2501.2020.09.015

Previous Articles     Next Articles

Research progress of mitochondrial toxicity evaluation model for nucleoside drugs

ZHANG Pinghu 1,2, ZHANG Ling 2, LIU Changxiao 3   

  1. 1 Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225009, Jiangsu, China; 2 Qinghai Himalayana, Center for Experimental Animal, Xining 810000, Qinghai, China; 3 Tianjin Institute of Materia Medica, Tianjin 300193, China

  • Received:2020-04-10 Revised:2020-08-10 Online:2020-09-26 Published:2020-09-30

Abstract: Antiviral nucleoside drugs represented by zidovudine, lamivudine, telbivudine, ribavirin, etc. have become the first choice drugs for clinical treatment of viral diseases such as AIDS, hepatitis B, herpes. However, the above drugs not only can inhibit virus replication, they can also interfere with the host mitochondrial mtDNA replication through similar mechanisms, leading to mitochondrial toxicity-related adverse reactions. Therefore, both the routine safety evaluation and mitochondrial toxicity evaluation are required for the development of nucleoside drugs. The research progress of mitochondrial toxicity evaluation models of nucleoside drugs are summarized for reference.

Key words: Himalayana Marmota, nucleoside drugs, mitochondrial toxicity, virus

CLC Number: